GenScript Biotech’s Associate Legend Biotech Schedules Late-Breaking Oral at EHA 2026 to Reveal Initial Phase 1 In Vivo CAR-T Data for LB2501 in R/R B-NHL

Bulletin Express

Jun 02

GenScript Biotech Corporation (GenScript; 01548.HK) released a voluntary announcement on 2 June 2026, noting that its associate company, Legend Biotech Corporation, will deliver a late-breaking oral presentation at the European Hematology Association (EHA) 2026 Congress in Stockholm (11–14 June 2026).

Legend Biotech’s presentation will feature promising preliminary clinical results from the Phase 1 study of LB2501, an investigational in vivo CD19/CD20 dual-targeting CAR-T cell therapy for patients with relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). The data will be disclosed during the congress’s late-breaking session.

To support the disclosure, Legend filed a Form 6-K with the U.S. Securities and Exchange Commission on 2 June 2026 (New York time) and issued a corresponding press release, both accessible through the SEC and Legend Biotech investor websites.

GenScript reminded shareholders and potential investors to pay attention to investment risks and exercise caution when dealing in the company’s securities.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/1176047743"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1176047743\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1176047743?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-02 22:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1176047743","market":"us","top_or_hot":-1,"title":"GenScript Biotech’s Associate Legend Biotech Schedules Late-Breaking Oral at EHA 2026 to Reveal Initial Phase 1 In Vivo CAR-T Data for LB2501 in R/R B-NHL","media":"Bulletin Express","content":"<p>GenScript Biotech Corporation (GenScript; 01548.HK) released a voluntary announcement on 2 June 2026, noting that its associate company, Legend Biotech Corporation, will deliver a late-breaking oral presentation at the European Hematology Association (EHA) 2026 Congress in Stockholm (11–14 June 2026).</p>\n<p>Legend Biotech’s presentation will feature promising preliminary clinical results from the Phase 1 study of LB2501, an investigational in vivo CD19/CD20 dual-targeting CAR-T cell therapy for patients with relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). The data will be disclosed during the congress’s late-breaking session.</p>\n<p>To support the disclosure, Legend filed a Form 6-K with the U.S. Securities and Exchange Commission on 2 June 2026 (New York time) and issued a corresponding press release, both accessible through the SEC and Legend Biotech investor websites.</p>\n<p>GenScript reminded shareholders and potential investors to pay attention to investment risks and exercise caution when dealing in the company’s securities.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GenScript Biotech’s Associate Legend Biotech Schedules Late-Breaking Oral at EHA 2026 to Reveal Initial Phase 1 In Vivo CAR-T Data for LB2501 in R/R B-NHL</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGenScript Biotech’s Associate Legend Biotech Schedules Late-Breaking Oral at EHA 2026 to Reveal Initial Phase 1 In Vivo CAR-T Data for LB2501 in R/R B-NHL\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-06-02 22:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>GenScript Biotech Corporation (GenScript; 01548.HK) released a voluntary announcement on 2 June 2026, noting that its associate company, Legend Biotech Corporation, will deliver a late-breaking oral presentation at the European Hematology Association (EHA) 2026 Congress in Stockholm (11–14 June 2026).</p>\n<p>Legend Biotech’s presentation will feature promising preliminary clinical results from the Phase 1 study of LB2501, an investigational in vivo CD19/CD20 dual-targeting CAR-T cell therapy for patients with relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). The data will be disclosed during the congress’s late-breaking session.</p>\n<p>To support the disclosure, Legend filed a Form 6-K with the U.S. Securities and Exchange Commission on 2 June 2026 (New York time) and issued a corresponding press release, both accessible through the SEC and Legend Biotech investor websites.</p>\n<p>GenScript reminded shareholders and potential investors to pay attention to investment risks and exercise caution when dealing in the company’s securities.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01548","symbol_name":"金斯瑞生物科技","start_time":0,"source_url":"","article_id":"1176047743","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1176047743","pubTimestamp":1780411453,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"GenScript Biotech Corporation (GenScript; 01548.HK) released a voluntary announcement on 2 June 2026, noting that its associate company, Legend Biotech Corporation, will deliver a late-breaking oral...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01548":"金斯瑞生物科技"},"translate_title":"金斯瑞生物科技(GenScript Biotech)的合作伙伴传奇生物科技(Legend Biotech)计划在EHA 2026上发布最新的口服药物，以揭示LB2501治疗R/R B-NHL的初始1期体内CAR-T数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01548":1},"content_text":"GenScript Biotech Corporation (GenScript; 01548.HK) released a voluntary announcement on 2 June 2026, noting that its associate company, Legend Biotech Corporation, will deliver a late-breaking oral presentation at the European Hematology Association (EHA) 2026 Congress in Stockholm (11–14 June 2026).\nLegend Biotech’s presentation will feature promising preliminary clinical results from the Phase 1 study of LB2501, an investigational in vivo CD19/CD20 dual-targeting CAR-T cell therapy for patients with relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). The data will be disclosed during the congress’s late-breaking session.\nTo support the disclosure, Legend filed a Form 6-K with the U.S. Securities and Exchange Commission on 2 June 2026 (New York time) and issued a corresponding press release, both accessible through the SEC and Legend Biotech investor websites.\nGenScript reminded shareholders and potential investors to pay attention to investment risks and exercise caution when dealing in the company’s securities.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}